News Overview

On approval, the firm will allot up to 3,000 NCDs of face value ₹10 lakh each.

EBITDA margin also rose to 32.2%, compared to 30.9% last year corresponding quarter

Third-party cargo represented 49% of total, up from 40% in FY24, the result of greater reliance on non-captive business.

Revenue for the year increased 20% YoY to ₹4,829 crore, led by increased cargo tonnage and consolidation of acquired units.

The bank's core operating income, or net interest revenue (NII), rose 8.3% year on year at ₹2,377.4 crore, reflecting sustained business growth

Of the total, ₹1,082 crore worth of projects were secured by the building division. The remaining ₹581 crore worth of orders were bagged by the transport division.

Total operating revenue was ₹2,134 crore in the quarter even with last year overall, and showing steady sales in its core verticals

Quarterly revenues were 28% higher year on year at ₹4,988.4 crore from ₹3,912.7 crore in Q4 FY24.

Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US